ICC International Cannabis Corp. announced that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Under the terms of the Agreement, ICC will supply NUBU will a suite of full-spectrum pharmaceutical grade medical cannabis products including: Packaged and labelled medical cannabis including; oil/tincture and capsules in finished goods form. ICC Branded, co-branded and/or ICC labelled medical cannabis products under development including but not limited to: Cannabis oil; Capsules; Transdermal patches; Oral sprays; Inhalers; and Vaporizing cartridges. Hemp derived CBD adhering to the international standard of less than 0.3% THC, in both bulk form (i.e. CBD isolate, CBD distillate, full spectrum oil) and finished good forms. ICC will leverage its existing brand portfolio, European GMP-certified processing facilities and extraction ready inventories to maximize margins and profitability, while servicing New Zealand’s high value patient population. The Company remains committed to servicing all links of the cannabis value chain including the manufacture and export of finished product to developing international marketplaces.